Flag of the European Union EU Clinical Trials Register Help

Clinical trials for pancreatic cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    57 result(s) found for: pancreatic cancer. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-000639-29 Sponsor Protocol Number: ABCSG_P00 Start Date*: 2013-03-27
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: A prospective, open, randomized, academic phase II, two-arm trial evaluating the effect of fibrin-coated collagen (TachoSil®) on postoperative pancreatic leakage and fistula formation from the panc...
    Medical condition: pancreatic surgery - evaluation of the effect of fibrin-coated collagen
    Disease: Version SOC Term Classification Code Term Level
    18.0 10017947 - Gastrointestinal disorders 10049192 Pancreatic fistula PT
    18.0 100000004863 10050457 Pancreatic anastomotic leak LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006055-33 Sponsor Protocol Number: HypoGI Start Date*: 2023-03-05
    Sponsor Name:Medical University of Vienna
    Full Title: Assessing the feasibility of pharmacologically induced hypothyroidism in patients with advanced pancreatic cancer - a pilot study
    Medical condition: Patients with newly diagnosed metastatic pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001714-15 Sponsor Protocol Number: Met.Panc.01 Start Date*: 2013-07-23
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie
    Full Title: Phase II trial of capecitabine (Xeloda®) + nab-paclitaxel (Abraxane®) in patients with metastatic pancreatic cancer
    Medical condition: metastatic pancreatic adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003489-28 Sponsor Protocol Number: VITDCUT Start Date*: 2018-02-19
    Sponsor Name:Medizinische Universität Graz
    Full Title: Influence of high dose vitamin D3 intake on outcome in pancreatic cancer surgery: prospective, randomized, open, controlled study
    Medical condition: vitamin D deficiency - pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004519-32 Sponsor Protocol Number: AVANeo1 Start Date*: 2005-11-28
    Sponsor Name:Medical University Vienna, Dept. of surgery
    Full Title: A randomised controlled pilot study of the efficacy of adding bevacizumab to gemcitabine as neoadjuvant treatment for locally advanced non metastatic pancreatic cancer - Neo-Avastin
    Medical condition: locally advanced non-metastatic pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000590-21 Sponsor Protocol Number: FFC33-24 Start Date*: 2005-08-24
    Sponsor Name:Faustus Forschung Compagnie, Translational Cancer Research GmbH
    Full Title: A Phase II Study of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)-urea (HECNU) in pancreatic cancer
    Medical condition: Pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001028-21 Sponsor Protocol Number: ABCSG_P01 Start Date*: 2013-05-17
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: P01 - A prospective, randomized, multicenter trial of additional radiochemotherapy to neoadjuvant chemotherapy in patients with locally advanced pancreatic adenocarcinoma
    Medical condition: locally advanced pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10051971 Pancreatic adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001850-24 Sponsor Protocol Number: ABCSG_P02 Start Date*: 2012-08-10
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: A prospective randomized phase II trial of FOLFIRINOX alone versus FOLFIRINOX followed by radiochemotherapy in patients with locally advanced, primarily inoperable pancreatic cancer
    Medical condition: locally advanced, primarily inoperable pancreatic carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005253-22 Sponsor Protocol Number: 1216.10 Start Date*: 2006-07-24
    Sponsor Name:Boehringer Ingelheim Austria GmbH
    Full Title: An open, randomised, clinical phase II trial in patients with unresectable advanced pancreatic cancer investigating the efficacy, safety, and pharmacokinetics of BI 2536 administered in repeated 3-...
    Medical condition: patients with unresectable (locally advanced or metastatic) pancreatic cancer, either chemonaive or after first-line chemotherapy with a gemciatbine based regimen
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000616-28 Sponsor Protocol Number: AGMT_DISCOVER Start Date*: 2019-07-16
    Sponsor Name:AGMT gGmbH
    Full Title: Multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of Dronabinol in the Improvement of ChemOthErapy-induced and tumor-Related...
    Medical condition: Advanced pancreatic (locally advanced, inoperable or metastatic) cancer during first-line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005559-34 Sponsor Protocol Number: AIO-PAK-0313 Start Date*: 2015-01-19
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Neoadjuvant plus adjuvant or only adjuvant nab-Paclitaxel plus Gemcitabine for resectable pancreatic cancer - The AIO-NEONAX trial (AIO-PAK-0313) A prospective, randomized, controlled, phase II st...
    Medical condition: Resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033608 Pancreatic cancer resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011101-16 Sponsor Protocol Number: P04722 Start Date*: 2009-11-02
    Sponsor Name:Schering-Plough Research Institute, A Division of Schering Corporation
    Full Title: Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination with Different Treatment Regimens in Subjects with Advanced Solid Tumors (Phase 1b/2; Protocol No. P04722)
    Medical condition: Colorectal Adenocarcinoma, Non-small Cell Lung Cancer, Gastric Adenocarcinoma, Her2+ Breast Cancer, Renal Cell Cancer, Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001150 Adenocarcinoma gastric LLT
    12.0 10065430 HER-2 positive breast cancer LLT
    12.0 10038407 Renal cell cancer LLT
    12.0 10051971 Pancreatic adenocarcinoma LLT
    12.0 10052360 PT
    12.0 10061873 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004675-31 Sponsor Protocol Number: AMCmedonc17-010 Start Date*: 2019-11-13
    Sponsor Name:Academic Medical Center
    Full Title: A randomized Phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on firs...
    Medical condition: pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003428-30 Sponsor Protocol Number: ACE-ST-004 Start Date*: 2016-01-26
    Sponsor Name:Acerta Pharma BV
    Full Title: A Phase 2, Randomized, Proof-of-Concept Study of Nab-Paclitaxel/Gemcitabine Alone and in Combination with ACP-196 in Subjects with Previously Untreated Metastatic Pancreatic Cancer
    Medical condition: Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003866-15 Sponsor Protocol Number: ABI-007-PANC-CA046C Start Date*: 2014-01-24
    Sponsor Name:Celgene Corporation
    Full Title: MPACT EXTENSION STUDY: MULTICENTER, SURVIVAL DATA COLLECTION IN SUBJECTS PREVIOUSLY ENROLLED IN PROTOCOL CA046
    Medical condition: Metastatic Adenocarcinoma of the Pancreas
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000294-39 Sponsor Protocol Number: INCB18424-363 Start Date*: 2014-07-16
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who ...
    Medical condition: Advanced or metastatic adenocarcinoma of the pancreas in patients that have failed or are intolerant to first-line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033607 Pancreatic cancer recurrent LLT
    17.1 100000004864 10033606 Pancreatic cancer non-resectable LLT
    17.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    17.1 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Prematurely Ended) DK (Completed) PT (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001852-38 Sponsor Protocol Number: EFC10203 Start Date*: 2007-12-21
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of S-1 as a Single Agent at 30 mg/m2 BID versus 5-FU Bolus Infusion for the Treatment of Patients with Metastatic Panc...
    Medical condition: Advanced Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033609 Pancreatic carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) SE (Completed) GR (Completed) DK (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004516-21 Sponsor Protocol Number: IMMU-107-04 Start Date*: 2014-09-16
    Sponsor Name:Immunomedics, Inc.
    Full Title: An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastat...
    Medical condition: Metastatic (Stage IV) Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) ES (Prematurely Ended) FR (Completed) PL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001467-39 Sponsor Protocol Number: GETNE1509 Start Date*: 2015-07-24
    Sponsor Name:GETNE (Grupo Español de Tumores Neuroendocrinos)
    Full Title: A phase II study to evaluate the safety and efficacy of lenvatinib in patients with advanced grade 1/2 neuroendocrine neoplasmas of pancreatic and extrapancreatic origin.
    Medical condition: Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO classification neuroendocrine tumors of the pancreas after progression to a previous targeted agent (cohor...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000293-20 Sponsor Protocol Number: INCB18424-362 Start Date*: 2014-07-31
    Sponsor Name:Incyte Corporation
    Full Title: INCB 18424-362 A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of ...
    Medical condition: Male or female, 18 years or older with histologically or cytologically confirmed adenocarcinoma of the pancreas that is inoperable or metastatic.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    17.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 09:50:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA